
Hybribio
Hybribio, a leader in molecular diagnostic products in China, is engaged in the nucleic acid diagnostic field. It provides a full operation chain from research and development to production and sales. The company's capabilities are enriched by an extensive product line catering to various medical diagnostic needs, including solutions for cancer DNA methylation, HPV detection, respiratory tract infections, and reproductive health diagnostics. Hybribio has been listed on the GEM of the Shenzhen Stock Exchange since 2017, a milestone that underscores its impact in the biotech sector. The company actively engages in combating viral outbreaks with tools such as the Monkeypox Virus Real-time PCR Kit, highlighting its role in public health crisis management. Additionally, Hybribio's devices have secured FDA approval, emphasizing their adherence to international standards. Hybribio continues to contribute to medical advancements and improvements in human health globally, driven by a commitment to innovation and quality.
Company details
Find locations served, office locations.
- Business Type:
- Manufacturer
- Industry Type:
- Medical / Health Care
- Market Focus:
- Globally (various continents)